Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study

被引：0
|
作者：
Fiorillo, Loretta [1 ]
Becker, Emily [2 ]
de Lucas, Raul [3 ]
Belloni-Fortina, Anna [4 ]
Maes, Peter [5 ]
Oberoi, Rajneet K. [5 ]
Paris, Maria [5 ]
Zhang, Wendy [5 ]
Zhang, Zuoshun [5 ]
Arkin, Lisa
机构：
[1] Univ Alberta, Stollery Childrens Hosp, Edmonton, AB, Canada
[2] Driscoll Childrens Hosp, Corpus Christi, TX USA
[3] Hosp Univ La Paz PPDS, Madrid, Spain
[4] Azienda Osped Univ Padova, Padua, Italy
[5] Amgen Inc, Thousand Oaks, CA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42163
引用
收藏
页码：AB122 / AB122
页数：1
相关论文
共 50 条
  • [31] RISANKIZUMAB EFFICACY/SAFETY IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS FROM IMMHANCE
    Blauvelt, Andrew
    Papp, Kim A.
    Gooderham, Melinda
    Langley, Richard G.
    Leonardi, Craig
    Lacour, Jean-Philippe
    Philipp, Sandra
    Tyring, Stephen
    Bukhalo, Michael
    Wu, Jashin J.
    Bagel, Jerry
    Frankel, Ellen H.
    Pariser, David
    Flack, Mary
    Scherer, Joseph
    Geng, Ziqian
    Gu, Yihua
    Camez, Anne
    Thompson, Elizabeth H. Z.
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 30 - 30
  • [32] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
    Armstrong, April W.
    Gooderham, Melinda
    Warren, Richard B.
    Papp, Kim A.
    Strober, Bruce
    Thaci, Diamant
    Morita, Akimichi
    Szepietowski, Jacek C.
    Imafuku, Shinichi
    Colston, Elizabeth
    Throup, John
    Kundu, Sudeep
    Schoenfeld, Steve
    Linaberry, Misti
    Banerjee, Subhashis
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : 29 - 39
  • [33] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
    Gordon, Kenneth B.
    Foley, Peter
    Krueger, James G.
    Pinter, Andreas
    Reich, Kristian
    Vender, Ronald
    Vanvoorden, Veerle
    Madden, Cynthia
    White, Katy
    Cioffi, Christopher
    Blauvelt, Andrew
    LANCET, 2021, 397 (10273): : 475 - 486
  • [34] Efficacy and safety of ixekizumab in a phaseIII, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)
    Paller, A. S.
    Seyger, M. M. B.
    Alejandro Magarinos, G.
    Bagel, J.
    Pinter, A.
    Cather, J.
    Keller, S.
    Rodriguez Capriles, C.
    Gontijo Lima, R.
    Gallo, G.
    Little, C. A.
    Edson-Heredia, E.
    Li, L.
    Xu, W.
    Papp, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) : 231 - 241
  • [35] Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-MorbiditiesSubanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
    Alexa B. Kimball
    Arielle G. Bensimon
    Annie Guerin
    Andrew P. Yu
    Eric Q. Wu
    Martin M. Okun
    Yanjun Bao
    Shiraz R. Gupta
    Parvez M. Mulani
    American Journal of Clinical Dermatology, 2011, 12 : 51 - 62
  • [36] Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study
    Strober, Bruce
    Bagel, Jerry
    Lebwohl, Mark
    Gold, Linda Stein
    Jackson, J. Mark
    Chen, Rongdean
    Goncalves, Joana
    Levi, Eugenia
    Duffin, Kristina Callis
    JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (08) : 801 - 808
  • [37] Efficacy and safety of certolizumab pegol, in patients with chronic plaque psoriasis: Preliminary results of a randomized, double-blind, placebo-controlled trial
    Reich, K.
    Tasset, C.
    Ortonne, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 251 - 251
  • [38] Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
    Ohtsuki, Mamitaro
    Kubo, Hiroshi
    Morishima, Hitomi
    Goto, Ryosuke
    Zheng, Richuan
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2018, 45 (09): : 1053 - 1062
  • [39] Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study
    Dogra, Sunil
    Krupashankar
    Budamakuntla, Leelavathy
    Srinivas, C. R.
    Khopkar, Uday
    Gupta, Sandesh
    Shetty, Narendra
    Pratap, Dasiga Venkata Subrahmanya
    Gopal, M. G.
    Rao, T. Narayana
    Garg, Vijay
    Sumathy, T. K.
    Saraswat, Abir
    Bhat, Ramesh
    Kura, Mahendra
    Pandey, Neeraj
    Shah, Radha
    Krishna, Kotla Sai
    Padmaja, Dalavai
    Manmohan, G.
    Ramakrishnan, M. S.
    Barve, Abhijit
    Montero, Enrique
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (02) : 331 - 333
  • [40] Phase 1b randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of GLPG3667 in patients with moderate-to-severe plaque psoriasis
    Thaci, Diamant
    Molnar, Judit
    Timmis, Helen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB92 - AB92
12345